Table 1. Univariate analysis for chemotherapy response and progression-free survival by clinical variables.
| Variables | No. of cases | Response to chemotherapy | Progression-free survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Responders (CR+PR) | Non-responders (SD+PD) | OR (95% CI) | P | MST, mon | 95% CI | Log-rank P | HR (95% CI) | P | |||
| Overall | 266 | 223 (83.8) | 43 (16.2) | 16.6 | 15.4–18.5 | ||||||
| Age, yr | |||||||||||
| < 65 | 121 | 101 (83.5) | 20 (16.5) | 1.00 | 15.4 | 12.4–8.2 | 1.00 | ||||
| ≥ 65 | 145 | 122 (84.1) | 23 (15.9) | 1.05 (0.55–2.02) | 0.883 | 18.2 | 15.9–21.6 | 0.145 | 0.81 (0.61–1.08) | 0.146 | |
| Gender | |||||||||||
| Male | 93 | 78 (83.9) | 15 (16.1) | 1.00 | 15.4 | 11.6–18.3 | 1.00 | ||||
| Female | 173 | 145 (83.8) | 28 (16.2) | 0.99 (0.50–1.98) | 0.991 | 17.4 | 16.0–19.6 | 0.099 | 0.78 (0.57–1.05) | 0.100 | |
| Smoking status | |||||||||||
| Never | 179 | 148 (82.7) | 31 (17.3) | 1.00 | 17.4 | 15.9–19.4 | 1.00 | ||||
| Ever | 87 | 75 (86.2) | 12 (13.8) | 1.31 (0.63–2.69) | 0.464 | 15.4 | 11.6–18.3 | 0.484 | 1.16 (0.82–1.52) | 0.484 | |
| Clinical stage | |||||||||||
| Ⅲ | 19 | 14 (73.7) | 5 (26.3) | 1.00 | 23.6 | 7.59–N.D. | 1.00 | ||||
| Ⅳ | 247 | 209 (84.6) | 38 (15.4) | 1.96 (0.67–5.77) | 0.219 | 16.4 | 15.1–18.3 | 0.096 | 1.71 (0.90–3.24) | 0.100 | |
| PS ECOG | |||||||||||
| 0–1 | 86 | 74 (86.1) | 12 (13.9) | 1.00 | 19.4 | 16.6–23.6 | 1.00 | ||||
| 2 | 180 | 149 (82.8) | 31 (17.2) | 0.78 (0.38–1.61) | 0.499 | 15.5 | 12.5–17.4 | 0.011 | 1.49 (1.09–2.03) | 0.011 | |
| Weight loss | |||||||||||
| No | 166 | 136 (81.9) | 30 (73.7) | 1.00 | 16.4 | 13.0–18.5 | 1.00 | ||||
| Yes | 19 | 14 (18.1) | 5 (26.3) | 0.62 (0.21–1.85) | 0.388 | 15.4 | 6.9–29.4 | 0.837 | 1.06 (0.62–1.80) | 0.837 | |
| EGFR mutation | |||||||||||
| Exon 19 deletion | 148 | 129 (87.2) | 19 (12.8) | 1.00 | 17.4 | 15.5–19.4 | 1.00 | ||||
| Exon 21 L858R | 111 | 87 (78.4) | 24 (21.6) | 0.53 (0.28–1.03) | 0.063 | 15.2 | 10.6–18.5 | 1.21 (0.91–1.62) | 0.193 | ||
| Othersa | 7 | 7 (100.0) | 0 (0.0) | – | 0.984 | 32.1 | 8.6–32.1 | 0.286 | 0.65 (0.21–2.05) | 0.463 | |
| EGFR-TKI | |||||||||||
| 1st generation | 166 | 135 (81.3) | 31 (18.7) | 1.00 | 15.9 | 12.4–17.4 | 1.00 | ||||
| 2nd generation | 100 | 88 (88.0) | 12 (12.0) | 1.68 (0.82–3.45) | 0.155 | 18.5 | 15.6–24.1 | 0.065 | 0.75 (0.56–1.02) | 0.067 | |
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, OR = odds ratio, MST = median survival time, CI = confidence interval, HR = hazard ratio, PS = performance status, ECOG = Eastern Cooperative Oncology Group, N.D. = not determined.
aUncommon EGFR mutations; two G719A, three G719X and two S768I.